┌──────────────────────────────────────────────────────────────┐ RECORD TYPE ......... SUBJECT FILE SUBJECT TYPE ........ EVENT FILE OPENED ......... 2026-07-05 17:21 UTC APPEARANCES ......... 6 ANNOTATIONS KNOWN ALIASES ....... 1 └──────────────────────────────────────────────────────────────┘
Paroxetine (Paxil/Seroxat)
ALSO APPEARS AS
- Paroxetine (Paxil/Seroxat)
APPEARS IN THE MARGINS OF
- Study 329: Paroxetine Clinical Trial Data Suppression and Publication Bias
Study 329 was an eight-week, placebo-controlled, double-blind randomized clinical trial of paroxetine (Paxil/Seroxat) in adolescents with depression, conducted in the late 1990s and published in 2001.…
- GSK Contractual Restrictions on Paroxetine Research Publication
This investigation concerns whether GlaxoSmithKline (GSK) contractually restricted Martin Keller's ability to publish findings unfavorable to the antidepressant paroxetine (marketed as Paxil/Seroxat),…
- Study 329 Ghostwriting: Prior Disclosure in Review Boards or Journals
Study 329 was a clinical trial of the antidepressant paroxetine (Paxil) for adolescents with major depressive disorder, conducted by SmithKline Beecham (later GlaxoSmithKline) from 1994 to 1998. The o…
- Study 329: FDA and International Regulatory Investigations into Adverse Event Reporting
Study 329, a clinical trial for the antidepressant paroxetine (Paxil/Seroxat) in adolescents, has been the subject of allegations regarding selective reporting of adverse events. Concerns primarily ce…
- GSK Paroxetine Trials: Publication Rights and Ghostwriting Agreements
This dossier investigates the availability of contractual agreements between GlaxoSmithKline (GSK) and individual researchers, such as Martin Keller, involved in paroxetine clinical trials, particular…
- GlaxoSmithKline Financial Impact from Adolescent Paroxetine Prescriptions (2001-2015)
This dossier investigates the financial impact on GlaxoSmithKline (GSK) from adolescent paroxetine prescriptions between 2001 and 2015, following the publication of Study 329. Study 329, published in …